BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36879149)

  • 41. [CEBPA gene mutation analysis in acute myeloid leukemia].
    Han C; Lin D; Ai XF; Wang F; Sun HY; Wang M; Mi YC; Wang JX; Ru K
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):566-71. PubMed ID: 23906447
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Roles of CEBPA mutation and expression abnormality in acute myeloid leukemia - review].
    Wang LM; Xiao HW; Huang H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1256-60. PubMed ID: 23114160
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.
    Wouters BJ; Löwenberg B; Erpelinck-Verschueren CA; van Putten WL; Valk PJ; Delwel R
    Blood; 2009 Mar; 113(13):3088-91. PubMed ID: 19171880
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CEBPA copy number variations in normal karyotype acute myeloid leukemia: Possible role of breakpoint-associated microhomology and chromatin status in CEBPA mutagenesis.
    Libura M; Pawełczyk M; Florek I; Matiakowska K; Jaźwiec B; Borg K; Solarska I; Zawada M; Czekalska S; Libura J; Salamanczuk Z; Jakóbczyk M; Mucha B; Duszeńko E; Soszyńska K; Karabin K; Piątkowska-Jakubas B; Całbecka M; Gajkowska-Kulig J; Gadomska G; Kiełbiński M; Ejduk A; Kata D; Grosicki S; Kyrcz-Krzemień S; Warzocha K; Kuliczkowski K; Skotnicki A; Jęrzejczak WW; Haus O
    Blood Cells Mol Dis; 2015 Dec; 55(4):284-92. PubMed ID: 26460249
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular evaluation of CEBPA gene mutation in normal karyotype acute myeloid leukemia: a comparison of two methods and report of novel CEBPA mutations from Indian acute myeloid leukemia patients.
    Ahmad F; Rajput S; Mandava S; Das BR
    Genet Test Mol Biomarkers; 2012 Jul; 16(7):707-15. PubMed ID: 22731647
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Recent Advances of Research on CEBPA Mutation in Acute Myeloid Leukemia].
    Yu WQ; Sun JN; Tan YH; Cui JW; Li W
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Dec; 23(6):1791-5. PubMed ID: 26708912
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FLT3-ITD and CEBPA Mutations Predict Prognosis in Acute Myelogenous Leukemia Irrespective of Hematopoietic Stem Cell Transplantation.
    Wang H; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    Biol Blood Marrow Transplant; 2019 May; 25(5):941-948. PubMed ID: 30503388
    [TBL] [Abstract][Full Text] [Related]  

  • 48.
    Mannelli F; Ponziani V; Bencini S; Bonetti MI; Benelli M; Cutini I; Gianfaldoni G; Scappini B; Pancani F; Piccini M; Rondelli T; Caporale R; Gelli AM; Peruzzi B; Chiarini M; Borlenghi E; Spinelli O; Giupponi D; Zanghì P; Bassan R; Rambaldi A; Rossi G; Bosi A
    Haematologica; 2017 Mar; 102(3):529-540. PubMed ID: 28250006
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population.
    Park SH; Lee HJ; Kim IS; Kang JE; Lee EY; Kim HJ; Kim YK; Won JH; Bang SM; Kim H; Song MK; Chung JS; Shin HJ
    Ann Lab Med; 2015 May; 35(3):288-97. PubMed ID: 25932436
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of CEBPA Mutations and Polymorphisms and their Prognostic Relevance in De Novo Acute Myeloid Leukemia Patients.
    Sarojam S; Raveendran S; Vijay S; Sreedharan J; Narayanan G; Sreedharan H
    Asian Pac J Cancer Prev; 2015; 16(9):3785-92. PubMed ID: 25987038
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Getting a handle on hereditary CEBPA mutations.
    DiNardo CD
    Blood; 2015 Sep; 126(10):1156-8. PubMed ID: 26337351
    [No Abstract]   [Full Text] [Related]  

  • 52. Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.
    Wen XM; Lin J; Yang J; Yao DM; Deng ZQ; Tang CY; Xiao GF; Yang L; Ma JC; Hu JB; Qian W; Qian J
    Int J Clin Exp Pathol; 2014; 7(10):6832-40. PubMed ID: 25400766
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features.
    Szankasi P; Ho AK; Bahler DW; Efimova O; Kelley TW
    Leuk Res; 2011 Feb; 35(2):200-7. PubMed ID: 20970189
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mutation of CEBPA in familial acute myeloid leukemia.
    Smith ML; Cavenagh JD; Lister TA; Fitzgibbon J
    N Engl J Med; 2004 Dec; 351(23):2403-7. PubMed ID: 15575056
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transformation from acute promyelocytic leukemia to acute myeloid leukemia with a CEBPA double mutation: A case report and review of the literature.
    Sun Y; Wang C; Sun Y; Wang J; Rong C; Wu A; Ouyang G; Sheng L
    Medicine (Baltimore); 2021 Feb; 100(5):e24385. PubMed ID: 33592885
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.
    Taskesen E; Bullinger L; Corbacioglu A; Sanders MA; Erpelinck CA; Wouters BJ; van der Poel-van de Luytgaarde SC; Damm F; Krauter J; Ganser A; Schlenk RF; Löwenberg B; Delwel R; Döhner H; Valk PJ; Döhner K
    Blood; 2011 Feb; 117(8):2469-75. PubMed ID: 21177436
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A clinical grade sequencing-based assay for CEBPA mutation testing: report of a large series of myeloid neoplasms.
    Behdad A; Weigelin HC; Elenitoba-Johnson KS; Betz BL
    J Mol Diagn; 2015 Jan; 17(1):76-84. PubMed ID: 25468431
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations.
    Deng DX; Zhu HH; Liu YR; Chang YJ; Ruan GR; Jia JS; Jiang H; Jiang Q; Zhao XS; Huang XJ
    Leuk Lymphoma; 2019 Sep; 60(9):2181-2189. PubMed ID: 30773106
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia.
    Marcolin R; Guolo F; Minetto P; Clavio M; Manconi L; Ballerini F; Carli A; Passannante M; Colombo N; Carminati E; Pugliese G; Tedone E; Contini P; Mangerini R; Kunkl A; Miglino M; Cagnetta A; Cea M; Gobbi M; Lemoli RM
    Leuk Res; 2019 Nov; 86():106223. PubMed ID: 31557597
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of acute myeloid leukemia with del(9q) - Impact of the genes in the minimally deleted region.
    Naarmann-de Vries IS; Sackmann Y; Klein F; Ostareck-Lederer A; Ostareck DH; Jost E; Ehninger G; Brümmendorf TH; Marx G; Röllig C; Thiede C; Crysandt M
    Leuk Res; 2019 Jan; 76():15-23. PubMed ID: 30476680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.